The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

Roivant Sciences ( (ROIV) ) has shared an update. Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio ...

Coastal Financial Corporation (Nasdaq: CCB) (the "Company”, "Coastal", "we", "our", or "us"), the holding company for Coastal ...

Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1% ...

Most patients, 81.6% (594/728), entered with or achieved clear or almost clear skin (vIGA-AD=0 or 1) with VTAMA cream, 1% in the ADORING 3 open-label LTE study. - Patients who achieved complete ...

Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are ...